Instructions:
Clinical and pharmacological group
16.014 (Drug that regulates calcium and phosphorus metabolism)
Release form, composition and packaging
◊ Pink, oval-shaped, film-coated tablets with beveled edges, engraved “VITRUM” on one side and “OSTEOMAG” on the other; on a cross section, the core is white to gray.
| 1 tab. | |
| colecalciferol* (vit. D3) | 5 mcg (200 IU) |
| calcium (in the form of calcium carbonate from oyster shells) | 600 mg |
| magnesium (in oxide form) | 40 mg |
| copper (in oxide form) | 1 mg |
| zinc (in oxide form) | 7.5 mg |
| manganese (as sulfate) | 1.8 mg |
| boron (as sodium borate) | 250 mcg |
Excipients: microcrystalline cellulose - 20.7 mg, croscarmellose sodium - 80 mg, magnesium stearate - 20 mg.
Film shell composition: hypromellose - 19.345 mg, titanium dioxide - 10 mg, triacetin - 0.2 mg, charming red dye (E129) - 0.44 mg, sunset yellow dye (E110) - 0.1 mg, indigo carmine (E132) - 0.005 mg.
* - in the form of colecalciferol concentrate; contains edible fat, corn starch, gelatin, sucralose, alpha-tocopherol.
30 pcs. — polyethylene bottles (1) — cardboard packs. 60 pcs. — polyethylene bottles (1) — cardboard packs.
pharmachologic effect
A combined drug that regulates calcium metabolism.
The pharmacological effect of the drug is determined by the properties of its constituent ingredients.
Colecalciferol (vitamin D3) regulates the exchange of calcium and phosphorus in the body, participates in the formation of the bone skeleton, helps maintain bone structure, enhances the absorption of calcium in the intestine and the reabsorption of phosphorus in the renal tubules.
Magnesium in combination with colecalciferol enhances calcium absorption. Participates in the growth and mineralization of bones, prevents the formation of calcium oxalate stones.
Calcium is involved in the formation of bone tissue, blood pressure control, and in the process of blood clotting. Promotes the formation of bones, teeth, increases bone density, and maintains healthy skin. Reduces the risk of developing osteoporosis. Promotes normal functioning of the nervous and muscular systems. Zinc is involved in bone formation.
Manganese is involved in the process of energy formation, metabolism of proteins and fats, building bones and connective tissue, and osteosynthesis.
Copper affects the formation of bone mass, hemoglobin and red blood cells. Participates in the formation of collagen, which is part of bone tissue and connective tissue, and helps prevent osteoporosis.
Boron is involved in maintaining healthy bones and the metabolism of calcium, phosphorus and magnesium. Improves calcium absorption, reduces the risk of developing colecalciferol deficiency, and helps prevent postmenopausal osteoporosis.
Pharmacokinetics
The effect of the drug Vitrum Osteomag is the combined effect of its components, so kinetic observations are not possible; Collectively, the components cannot be traced using markers or bioassays.
Dosage
Adults and children over 12 years old - 1-2 tablets/day.
Overdose
Data on overdose of the drug Vitrum Osteomag are not provided.
Drug interactions
The drug slows down the absorption of tetracycline antibiotics, acetylsalicylic acid and other salicylates, sulfonamides, beta-blockers and indirect anticoagulants. In this regard, the drug is recommended to be used 2 hours before or 2 hours after taking other medications.
Use during pregnancy and lactation
The drug Vitrum Osteomag is used during pregnancy and lactation according to indications.
During the entire period of pregnancy and lactation, constant medical monitoring is required.
Side effects
From the digestive system: constipation, diarrhea, flatulence, epigastric pain, nausea.
Other: increased calcium levels in urine and blood with prolonged use of the drug in high doses.
Storage conditions and periods
It is recommended to store the drug in a dry place, out of reach of children, at a temperature of 10° to 30°C. Shelf life - 3 years.
Indications
Used as a therapeutic and prophylactic agent:
— replenishment of calcium and vitamin D3 deficiency in old age, during or after menopause;
— prevention of osteoporosis of various origins;
- treatment of senile osteoporosis and osteomalacia;
— complex therapy of osteoporosis and other metabolic osteopathies (in combination with special drugs).
Contraindications
- severe renal dysfunction;
- increased calcium levels in the blood (hypercalcemia);
- increased excretion of calcium in the urine (hypercalciuria);
- urolithiasis (formation of calcium stones);
- children under 12 years of age;
- hypersensitivity to vitamin D3 and other components of the drug.
special instructions
Use with caution in patients with sarcoidosis or renal failure.
Do not exceed recommended doses.
When using the drug, it should be taken into account that 2 tablets. Vitrum Osteomag satisfies the daily need for vitamin D3, calcium and magnesium.
Control of laboratory parameters
When used in large doses, monitoring of renal function is necessary. In case of long-term treatment, it is necessary to check the amount of calcium excreted in the urine.
Conditions for dispensing from pharmacies
The drug is approved for use as a means of OTC.
Vitrum Osteomag
Release form, composition and packaging
Pink coated tablets, capsule-shaped.
1 tab. colecalciferol 200 IU;
- calcium 600 mg;
- magnesium 40 mg;
- zinc 7.5 mg;
- manganese 1.8 mg;
- copper 1 mg;
- boron 250 mcg.
Clinical and pharmacological group: A drug that affects phosphorus-calcium metabolism. A drug for the treatment of osteoporosis.
pharmachologic effect
A combined drug that regulates calcium metabolism.
The pharmacological effect of the drug is determined by the properties of its constituent ingredients. Colecalciferol (vitamin D3) regulates the exchange of calcium and phosphorus in the body, participates in the formation of the bone skeleton, helps maintain bone structure, enhances the absorption of calcium in the intestine and the reabsorption of phosphorus in the renal tubules.
Magnesium in combination with colecalciferol enhances calcium absorption. Participates in the growth and mineralization of bones, prevents the formation of calcium oxalate stones. Calcium is involved in the formation of bone tissue, blood pressure control, and in the process of blood clotting.
Promotes the formation of bones, teeth, increases bone density, and maintains healthy skin. Reduces the risk of developing osteoporosis. Promotes the normal functioning of the nervous and muscular systems. Zinc is involved in bone formation.
Manganese is involved in the process of energy formation, metabolism of proteins and fats, building bones and connective tissue, and osteosynthesis.
Copper affects the formation of bone mass, hemoglobin and red blood cells. Participates in the formation of collagen, which is part of bone tissue and connective tissue, and helps prevent osteoporosis.
Boron is involved in maintaining healthy bones and the metabolism of calcium, phosphorus and magnesium. Improves calcium absorption, reduces the risk of developing colecalciferol deficiency, and helps prevent postmenopausal osteoporosis.
Pharmacokinetics
The effect of the drug Vitrum Osteomag is the combined effect of its components, so kinetic observations are not possible; Collectively, the components cannot be traced using markers or bioassays.
Indications
Used as a therapeutic and prophylactic agent:
- replenishment of calcium and vitamin D3 deficiency in old age, during or after menopause;
- prevention of osteoporosis of various origins;
- treatment of senile osteoporosis and osteomalacia;
- complex therapy of osteoporosis and other metabolic osteopathies (in combination with special drugs).
Dosage regimen
Adults and children over 12 years old - 1-2 tablets/day.
Side effect
- From the digestive system: constipation, diarrhea, flatulence, epigastric pain, nausea.
Other: increased calcium levels in urine and blood with prolonged use of the drug in high doses.
Contraindications
- severe renal dysfunction;
- increased calcium levels in the blood (hypercalcemia);
- increased excretion of calcium in the urine (hypercalciuria);
- urolithiasis (formation of calcium stones);
- children under 12 years of age;
- hypersensitivity to vitamin D3 and other components of the drug.
Pregnancy and lactation
The drug Vitrum Osteomag is used during pregnancy and lactation according to indications. During the entire period of pregnancy and lactation, constant medical monitoring is required.
special instructions
Use with caution in patients with sarcoidosis or renal failure. Do not exceed recommended doses. When using the drug, it should be taken into account that 2 tablets. Vitrum Osteomag satisfies the daily need for vitamin D3, calcium and magnesium.
Control of laboratory parameters
When used in large doses, monitoring of renal function is necessary. In case of long-term treatment, it is necessary to check the amount of calcium excreted in the urine.
Overdose
Data on overdose of the drug Vitrum Osteomag are not provided.
Drug interactions
The drug slows down the absorption of tetracycline antibiotics, acetylsalicylic acid and other salicylates, sulfonamides, beta-blockers and indirect anticoagulants. In this regard, the drug is recommended to be used 2 hours before or 2 hours after taking other medications.
Storage conditions and periods
It is recommended to store the drug in a dry place, out of reach of children, at a temperature of 10° to 30°C. Shelf life – 3 years.
Vitrum Osteomag No. 60 tablet p.o.
Instructions for use of the drug for specialists VITRUM® OSTEOMAG / VITRUM® OSTEOMAG Trade name VITRUM® OSTEOMAG International nonproprietary name no Dosage form and description Oval tablets, with a beveled edge, coated in pink color with engraving “VITRUM” on one side of the tablet and engraving “OSTEOMAG” on the other side of the tablet. Composition 1 film-coated tablet contains Vitamin D3 (colecalciferol) 200 IU Calcium (oyster) 600 mg Magnesium 40 mg Zinc 7.5 mg Copper 1 mg Manganese 1.8 mg Boron 250 mcg excipients: microcrystalline cellulose, stearic acid, magnesium stearate, maltodextrin, corn starch, sugar, crospovidone, titanium dioxide, hydroxypropyl methyl cellulose, triacetin, dyes. Pharmacotherapeutic group Multivitamins in other combinations. ATC code A11AB Pharmacological properties A drug that affects metabolic processes (regulator of calcium-phosphorus metabolism). Determined by the properties of its constituent ingredients. Vitamin D3 regulates the exchange of calcium and phosphorus in the body, participates in the formation of the bone skeleton, helps maintain bone structure, enhances the absorption of calcium in the intestines and the reabsorption of phosphorus in the renal tubules. Magnesium in combination with vitamin D3 increases calcium absorption, affects bone growth and mineralization, and prevents the formation of calcium oxalate stones. Calcium is involved in bone formation, blood pressure control and blood clotting. Promotes the formation of bones, teeth, increases bone density, and maintains healthy skin. Reduces the risk of developing osteoporosis. Promotes the normal functioning of the nervous and muscular systems. Zinc is involved in bone formation. Manganese is involved in the processes of energy formation, metabolism of proteins and fats, construction of bones and connective tissues, and osteosynthesis. Copper affects the formation of bone mass, hemoglobin and red blood cells. Participates in the formation of collagen, which is part of bone and connective tissue, and helps prevent osteoporosis. Boron is involved in maintaining healthy bones and the metabolism of calcium, phosphorus and magnesium. Improves calcium absorption, reduces the risk of developing vitamin D3 deficiency, and helps prevent postmenopausal osteoporosis. Indications for use Used as a therapeutic and prophylactic agent: - replenishment of calcium and vitamin D3 deficiency in old age, during or after menopause; — prevention of osteoporosis of various origins; treatment of senile osteoporosis and osteomalacia; - complex therapy of osteoporosis and other metabolic osteopathies in combination with anti-osteoporotic drugs. Directions for use and dosage: Adults and children over 12 years of age – 1-2 tablets per day. Two tablets satisfy the daily requirement for vitamin D, calcium and magnesium. Side effects Constipation or diarrhea, bloating, epigastric pain, nausea. With long-term use in high doses, an increase in calcium levels in the urine and blood is possible. Contraindications Severe renal dysfunction, increased calcium levels in the urine or blood, urolithiasis (formation of calcium stones), increased excretion of calcium in the urine. Hypersensitivity to vitamin D and other components of the drug. Children's age up to 12 years. When used in large doses, monitoring of renal function is necessary. In case of long-term treatment, it is necessary to check the amount of calcium excreted in the urine. During the entire period of pregnancy and lactation, constant medical monitoring is required. Use with caution in persons suffering from sarcoidosis or renal failure. Interactions with other drugs The drug slows down the absorption of tetracycline antibiotics, acetylsalicylic acid and other salicylates, sulfonamides, beta-blockers and indirect anticoagulants. In this regard, it is recommended to use it 2 hours before or 2 hours after taking other medications. Overdose Do not exceed the recommended dosage. Release form: 30 or 60 tablets in high-density polyethylene bottles, packed in a cardboard box. Storage conditions: At a temperature of 10-30° C, in a dry place. Keep out of the reach of children. Shelf life: 5 years. Do not use after the expiration date stated on the packaging. Conditions for dispensing from pharmacies Dispensed without a prescription. Manufacturer Unipharm, Inc., USA
